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Introduction {#sec001}
============

*Mycobacterium tuberculosis (M*.*tb)*, the causative agent of tuberculosis (TB), poses a serious health threat to the public worldwide. *M*.*tb* is an intracellular pathogen residing within the mononuclear phagocytes, has developed specific mechanisms to evade the host innate immune response which facilitate its long-term survival \[[@pone.0224239.ref001],[@pone.0224239.ref002]\]. Phagosome maturation and phago-lysosome fusion block, interference with antigen presentation, resistance to reactive oxygen and nitrogen intermediates \[[@pone.0224239.ref003],[@pone.0224239.ref004]\], alteration of host cell apoptotic pathways \[[@pone.0224239.ref005]\] and inhibition of autophagy in host cells \[[@pone.0224239.ref006]\] count among the strategies which enhance *M*.*tb* survival inside the macrophages.

A multitude of innate immune signaling pathways are involved in host defense against pathogens. During infection, the pathogen-associated molecular patterns of the microbes are recognized by host cells through various pattern recognition receptors. This recognition provokes an intracellular signaling cascade, resulting in activation of antimicrobial effector mechanisms to stimulate the clearance of the pathogens \[[@pone.0224239.ref007],[@pone.0224239.ref008]\]. Autophagy works as one of the effector mechanism downstream to these receptors and owing to this reason it forms an integral part of innate and adaptive immunity to various pathogens \[[@pone.0224239.ref009]\]. Recent reports have demonstrated that autophagy induction in macrophages plays a crucial role in the innate immune response to *M*.*tb* \[[@pone.0224239.ref010]\].

Previously, we have reported that MIP is a potent inducer of autophagy in macrophages which resulted in enhanced co-localization of *M*.*tb* as well as its clearance from the infected macrophages \[[@pone.0224239.ref011]\]. The next question asked was whether MIP induced autophagy was exclusively by active mechanisms i.e. presence of whole MIP is required or some of its component/s have the ability to induce autophagy. Reports suggest that mycobacterial gene products / individual fractions can affect or limit host autophagy responses to the pathogens \[[@pone.0224239.ref012]--[@pone.0224239.ref015]\]. The protein/lipid/DNA fractions of MIP were isolated and tested for their ability to modulate autophagy in RAW 264.7 macrophages. MIP lipid as well as DNA fraction was able to induce significant autophagic response in macrophages. LAM is considered to be one of the prominent components of the lipid fraction with an established immunomodulatory potential. LAM from pathogenic mycobacteria has been reported to impose block in the autophagic pathway and also limit the fusion of phagosomes with the lysosomes \[[@pone.0224239.ref016]--[@pone.0224239.ref018]\]; thus help the bacilli to escape host immune mechanisms and enhance their survival inside the macrophages. Furthermore, MIP is known to be non-pathogenic mycobacteria and its autophagy inducing potential is known, we speculated the possibility that LAM might play crucial role in inducing autophagy in macrophages.

To test this hypothesis, MIP-LAM was isolated and purified and analyzed for its immunostimulatory as well as autophagy modulating properties. MIP-LAM led to significant production of pro-inflammatory cytokines including TNF-α, IL-6 and IL-12. Also, MIP-LAM was able to induce autophagy in macrophages. Enhanced co-localization of *M*.*tb* within the phagolysosomes was observed in MIP-LAM stimulated macrophages which resulted in the increase in *M*.*tb* killing.

Materials and methods {#sec002}
=====================

Reagents and antibodies {#sec003}
-----------------------

RAW 264.7 (TIB-71^TM^) and J774.1macrophages (TIB-67^TM^) were obtained from ATCC. Roswell Park Memorial Institute medium-1640 (RPMI-1640) and Dulbecco\'s Modified Eagle Medium (DMEM) and Penicillin-Streptomycin antibiotic mixture were purchased from HiMedia Laboratories (Mumbai, India). Heat inactivated fetal bovine serum (FBS) was procured from Biological Industries (Israel). C57BL/6 mice were provided by small animal facility of National Institute of Immunology. Middlebrook 7H9 and Middlebrook 7H11-agar were obtained from Difco Laboratories, USA. MIP-LAM was prepared by us whereas *M*.*tb-*LAM (Cat. No. NR-14848), and monoclonal anti-LAM antibodies: CS-35 (Cat. No. NR-13811), and CS-40 (Cat. No. NR-13812) were procured from BEI resources (Virginia, USA). ELISA kits for TNF-α (Cat. No. 555268), IL-6 (Cat. No. 555240) and IL-12 (Cat. No. 555165) were procured from BD Biosciences (California, USA). Recombinant murine Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF; Cat. No. 315--03) was purchased from Peprotech Asia (Rehovot, Israel). Pierce BCA protein assay kit (Cat. No. 23252), DQ-BSA (Cat. No. D12051), Lysotracker-Red (Cat. No. L7528), 4, 6-Diamidino-2-phenylindole (DAPI; Cat. No. D1306), ProLong Gold antifade reagent (Cat. No. P36934) were obtained from Invitrogen, Thermo Fisher Scientific (Waltham, NY, USA). Hygromycin-B (Cat. No. H274), Clarity Western ECL substrate (Cat. No. 170--5061), BLUelf Prestained Protein Ladder (Cat. No. PM008), were respectively obtained from Sigma Aldrich, Merck (Darmstadt, Germany), BioRad Laboratories (Hercules, California, USA); Bio-Helix Co. Ltd. (Keelung, Taiwan). LC3-II/I antibody (Cat.No. 12741), β-actin (Cat.No. 5125) and horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG antibody (Cat. No. 7074) and Alexa fluor 488 mAb were obtained from Cell Signaling Technology (Danvers, MA).

Mycobacterial culture {#sec004}
---------------------

MIP and *M*.*tb* (H37Rv strain) were cultivated in Middlebrook 7H9 broth supplemented with 10% ADC at 100 rpm in 37°C. Plating was done on Middlebrook 7H11-OADC plates containing Hygromycin B (conc. 2 μg/ ml). Oleic acid, Catalase, Lowenstein-Jensen (LJ) Media were obtained from HiMedia Laboratories, India. GFP expressing *M*.*tb* was prepared by the method described in \[[@pone.0224239.ref011]\].

Cell culture {#sec005}
------------

RAW 264.7 and J774.1 macrophages were cultured in RPMI-1640 and DMEM respectively, supplemented with 10% FBS and 1 X antibiotic cocktail. For experiments, macrophages were harvested by centrifugation at 300 g for 10 min and counted using hemocytometer. Suitable dilution was prepared and cells were seeded and kept overnight at 37°C in a CO~2~ incubator for adherence.

Extraction of whole lipid fraction of MIP {#sec006}
-----------------------------------------

MIP culture (OD~600~ = 0.8--0.9) was harvested by centrifugation at 1000 g for 10 min. The cell pellet was resuspended in chloroform-methanol-PBS solution in the ratio of 8:4:3 and allowed to mix by stirring for 4--5 h. The contents were then left stagnant for 4--5 h at RT to allow the separation of chloroform-soluble fraction from the methanol-soluble fraction. The chloroform layer containing lipids was then separated and the solvent was evaporated using BUCHI Rotavapor R-200. The dried lipids were then collected, weighed and were stored at -20ଌ till further use.

Isolation of MIP genomic DNA {#sec007}
----------------------------

MIP genomic DNA isolation was done as per the protocol described in \[[@pone.0224239.ref019]\]. Briefly, 20--40 mL of MIP culture was harvested and the pellet was resuspended in 10 mL of Tris-EDTA buffer (TE buffer) and mixed gently. The mycobacterial suspension was heated at 80°C for 1 h in a water bath. The temperature of the suspension was lowered to 30°C and Lysozyme (final concentration 2 mg/ml) was added. The suspension was then incubated overnight at 37°C and thereafter, 1 ml of 10% SDS solution and 20 μl of 10 mg/ml Proteinase K solution (Final concentration- 20 μg/ml) was added. Equal volume of PCI mixture (Phenol:Chloroform:Isoamylalcohol in ratio of 25:24:1 v/v) was added and mixed properly. The resulting suspension was then centrifuged at 12,000 g for 10 min at 4°C. The aqueous phase was collected and 100 μg of 3 M sodium acetate solution per ml of aqueous phase was added to it and mixed well. Equal volume of Isopropanol was added and kept at stagnant position for 5--10 min. The suspension containing precipitated DNA was again centrifuged at 12,000 g for 10 min at 4°C. Subsequently, the pellet was washed with 75% ethanol and air dried. Finally, the pellet was dissolved in molecular grade water and was analyzed by agarose gel electrophoresis using Bio Rad Gel Doc XR^**+**^ System.

Extraction of total MIP proteins {#sec008}
--------------------------------

MIP culture was harvested and washed with PBS followed by lysis for 30 min on ice using lysis buffer. The lysed mycobacterial cells were sonicated 3 times for 20 sec at 50% power using a QSonica Ultrasonic Digital Sonicator to release protein followed by centrifugation at 11,000 rpm for 20 min at 4°C. The supernatant was collected and concentrated using an Amicon Ultra Centrifugal Filter with molecular weight cut-off of 10,000 kDa until a concentration of 1--2 mg/ml was achieved. The protein sample was confirmed using SDS PAGE and subsequently protein concentrations were determined using BCA assay.

LC3 Western blotting {#sec009}
--------------------

The cellular lysates were prepared using M-2 lysis buffer (1 M Tris pH 7.4; 5 M NaCl; Glycerol; 10% Triton-X-100; 0.5 M EDTA; 0.5 M EGTA) containing 1 X PIC (Protease Inhibitor Cocktail). The protein content of cell lysates was determined using BCA method of protein estimation and expression of LC3 was evaluated using Western blotting. Briefly, 20 μg of each protein sample was loaded on 15% SDS gel and electrophoresis was done. The proteins on the gel were then transferred onto Polyvinylidenedifluoride (PVDF) membrane using wet transfer at 60 V for 2.5 h. Blocking was done at RT for 1 h using 5% w/v skimmed milk prepared in 1 X TBST (Tris-buffered saline with 0.1% Tween-20). Subsequently membrane was incubated with LC3 II/I primary antibody (1:1000 dilution in 5% w/v Bovine Serum Albumin in TBST) for overnight at 4°C. This was followed by incubating the membrane for 1 h with HRP tagged secondary antibody (1:5000 dilution in TBST) at RT. Thereafter, the proteins were detected by chemiluminescence and images were analyzed using ImageJ software.

Purification of MIP lipoarabinomannan {#sec010}
-------------------------------------

Cell wall was prepared by method followed by our group \[[@pone.0224239.ref020]\]. Briefly, MIP culture in mid log growth phase was harvested by centrifugation at 3000 g for 10 min. The pellet was washed with PBS, resuspended in cold PBS and passed through French press twice at 40,000 kPa. The resulting suspension was centrifuged at 10,000 g for 15 min and the pellet was discarded. Supernatant was again centrifuged at 27,000 g for 30 min. The pellet consisting of cell wall was lyophilized. The dry cell wall was re-hydrated in PBS (10 g in 100 ml PBS) and the resulting suspension was sonicated at 40% efficiency for 15 min. The suspension was then centrifuged at 18,000 g for 30 min and supernatant was collected which was subsequently concentrated by vacuum evaporation. The concentrated supernatant was extracted with phenol (40% final concentration) for 1 h at 70°C. Aqueous phase was separated from phenol layer by low speed centrifugation (4000 g for 20 min) and phenol phase was extracted once more with water. The aqueous extracts from both extractions were combined and concentrated by vacuum evaporation to 50 ml final volume. This concentrated aqueous extract was extracted with four volumes of chloroform: methanol (2:1) for the removal of residual phenol. The aqueous phase having crude LAM was collected and evaporated to dryness. Crude LAM was re-suspended in PBS (10 mg in 1 ml PBS) and passed through sephacryl S-100 column equilibrated with PBS at flow rate of 0.5 ml/min and 3 ml fractions were collected. Each fraction was examined for carbohydrate and protein content by phenol-sulphuric acid method and BCA respectively.

Presence of LAM was detected by ELISA using reference mAbs CS-35 and CS-40 (1:1 ratio at dilution of 1:500). Fractions found positive for presence of LAM were pooled and concentrated by using an Omega cell (10 kDa molecular cut-off membrane). Finally, LAM was precipitated by ethanol at final concentration of 80%.

Carbohydrate content determination {#sec011}
----------------------------------

Carbohydrate content in each fraction obtained from sephacryl-S100 column was determined by phenol-sulphuric acid method. 50μl of each fraction was taken in 1.5 ml tube and 167 μl phenol (4%) and 834 μl H~2~SO~4~ (96%) were added to it. Contents were shaken and incubated for 10--20 min at RT. Subsequently, O.D. was measured by ELISA reader at 490 nm. Glucose was used as standard control.

ELISA for identification of LAM containing fractions {#sec012}
----------------------------------------------------

96-well ELISA plate was coated with 100 μl of each fraction overnight at RT. *M*.*tb-*LAM was used as standard. Plate was washed 4 times with PBST (Phosphate buffer saline + 0.05% Tween 20). Blocking was done using 1% BSA for 1 h at 37°C. Plate was washed thrice and 100 μl of mAbs CS-35 and CS-40 (dilution 1:1000 in PBS) were added, incubated for 1 h at RT. Plate was again washed and 100 μl of rabbit anti-mouse IgG-HRP conjugate (dilution 1:2000 in PBS) was added to the wells and incubated for 1 h at RT. Washing was done 5 times and subsequently 100 μl of TMB substrate was added to the wells. O.D. was measured at 450 nm by ELISA reader. Fractions found positive for LAM were pooled and concentrated by using an Omega cell (10 kDa molecular cut-off membrane). Finally, LAM was precipitated with ethanol (85% of total volume) and precipitate was collected, centrifuged and lyophilized.

SDS-PAGE andsilver stainingof LAM {#sec013}
---------------------------------

MIP-LAM was mixed with 1 X protein loading dye and heated at 95°C for 5 min and desired quantity was loaded on to 10% SDS-PAGE and run at 30 mA for 90 min.

Silver staining of LAM requires modification of silver staining protocol used for visualization of proteins on gel. In this method, LAM resolved gel was treated with 0.2% periodic acid for 2 min at 40°C before silver staining step. Gel was first placed in fixation solution overnight at 4°C. Subsequently, it was dipped in oxidation solution for 5 min with gentle agitation followed by washing thrice with ddH~2~O, each for 30 min. The gel was then transferred to a clean glass plate, staining solution was added to it and kept in shaking condition for 10 min. Gel was washed in ddH~2~O four times, each for 10 min with gentle agitation.

Western blot of LAM {#sec014}
-------------------

LAM sample resolved by SDS-PAGE was transferred on to polyvinylidenedifluoride membrane by diffusion method at 70°C for 30 min in transfer buffer (39 mM glycine, 48 mM Tris, 0.037% SDS and 15% methanol). The membrane was blocked by 5% BSA in PBS for 1 h at 37°C followed by three washes of 5 min each in PBST (PBS containing 0.05% tween-20). The membrane was then incubated with anti-LAM mAbs CS-35 and CS-40, diluted (1:1000) in PBST containing 5% BSA. The blot was again washed thrice with PBST and incubated for 1 h at RT with HRP conjugated anti-mouse secondary antibody (1:5000) prepared in 5% BSA-PBST. After three subsequent washes, the blot was developed using chemiluminescent substrate.

Derivation of dendritic cells from bone-marrow {#sec015}
----------------------------------------------

C57BL/6 mice (6--8 weeks old) were used for isolation of bone marrow dendritic cells (BMDCs). Femur and tibia from hind limb were removed aseptically and kept in complete RPMI medium after cleaning the muscular tissue. The bones were then washed for 2 min in 70% ethanol followed by two washes with RPMI medium. Bones were transferred to a sterile petri-dish and were cut open at both ends and subsequently flushed with 5 ml of complete RPMI medium using a syringe. Marrow plugs were passed from syringe once to break clumps and collected in a tube. Pellet of the marrow, obtained after centrifugation, was subjected to RBC lysis solution (3--4 ml Gey's solution for 3--5 min at RT) and washed twice at 300 g for 10 min. Cell density was adjusted to 1 × 10^6^ cells/ml in complete RPMI, supplemented with 20 ng/ml (700--1000 U/ml) of murine recombinant Granulocyte-macrophage colony-stimulating factor (GM-CSF) and the suspension was plated (4 ml/well) in 6-well plate. Exhausted media was aspirated following gentle shaking of plate (to remove non-adherent granulocytes and lymphocytes) and replenished with fresh RPMI medium supplemented with mGM-CSF at day 3 and day 5. At day 7, cells were dislodged by gentle pipetting and pooled in a tube. The cells were washed twice to remove GM-CSF before setting up the assay.

Analysis of immunomodulatory property of LAM {#sec016}
--------------------------------------------

J774.1 macrophages or bone marrow derived dendritic cells were plated at respective densities of 0.5 × 10^6^ or 1.0 × 10^6^ per well in 24-well culture plates. Varying concentrations of MIP-LAM and *M*.*tb-*LAM were added to the wells and incubated for 24 h. Culture supernatant was collected and concentrations of cytokines (TNF-α, IL-12 and IL-6) were measured by ELISA using commercially available ELISA kits, according to the manufacturer instructions.

NO and ROS estimation {#sec017}
---------------------

RAW macrophages were seeded at a density of 1.0 × 10^6^ per well in 12-well culture plates and stimulated with LPS (1 μg/mL) or MIP-LAM (5 μg/mL) for 24 h. Supernatant was collected and estimated for NO with Griess reagent.

For ROS estimation, the cell-permeant 2\',7\'-dichlorodihydrofluorescein diacetate (H~2~DCFDA) was used. The non-fluorescent H~2~DCFDA is converted to the highly fluorescent 2\',7\'-dichlorofluorescein (DCF) when the acetate groups are cleaved by intracellular esterases and oxidation. Briefly, macrophages were incubated with 20 μM H~2~DCFDA dye for 45 min at 37°C under dark conditions. Cells were then washed followed by stimulation with LPS (1 μg/mL) / MIP-LAM (5 μg/mL). Fluorescence was determined using fluorimeter, excitation at 490 nm and emission at 524 nm. H~2~O~2~ (100 μM) was used as a positive control.

Puncta formation assay {#sec018}
----------------------

RAW 264.7 cells were seeded on sterile coverslips (18 x 18 cm^2^) placed in 12-well plate and kept overnight for adherence. Next day, the macrophages were stimulated with varying concentrations of MIP-LAM or *M*.*tb-*LAM. After specified time-points, the cells were fixed using absolute methanol for 10 min. Permeabilization was done using 0.1% Triton-X-100 in PBS for 10 min at RT followed by blocking with 3% BSA (prepared in 0.1% Triton-X-100 in PBS) for 2 h at RT. Cells were then incubated overnight with anti-LC3 antibody (dilution-1:100) at 4ଌ and subsequent incubation with Alexa fluor 488 antibody (dilution-1:1000) for 45 to 60 min at RT. Slides were visualized using Zeiss LSM 510 Meta Confocal Microscope at 63 X magnification.

Co-localization of *M*.*tb* with lysosomes in LAM stimulated macrophages {#sec019}
------------------------------------------------------------------------

The protocol used in our previous publication was followed \[[@pone.0224239.ref011]\]. Briefly, macrophages were seeded on coverslips were infected with GFP expressing *M*.*tb* for 4 h with subsequent stimulation with MIP-LAM / *M*.*tb-*LAM for 4 h. This was followed by Lysotracker-Red staining. Fixation was done in 4% PFA for 10 min at RT with subsequent DAPI staining. Co-localization of *M*.*tb* expressing GFP with Lysotracker-red was examined by counting total number of green spots and yellow spots and % co-localization was calculated.

Assessment of *M*.*tb* survival by CFU assay {#sec020}
--------------------------------------------

1 x 10^6^ macrophages were seeded per well in a 12-well plate and infected with *M*.*tb* for 4 h at a MOI of 1:10. After washing out the extracellular bacteria, cells were stimulated with MIP-LAM / *M*.*tb-*LAM for 4 h. Cells were then washed and lysed for 10 min using 0.1% Triton X-100 prepared in PBS. From each group, 100 μl of lysate was plated on 7H11-agar plates in triplicates. After 22--28 days, the colonies were counted and percentage survival of *M*.*tb* was quantified.

Statistical analysis {#sec021}
--------------------

The data shown in this study were plotted as the mean ± standard error of the mean (SEM) of triplicate samples and were representative of at least three separate experiments. Comparisons were made among the groups by One-way analysis of variance (ANOVA) with a Bonferroni\'s post-test. P value of \<0.05 was considered as significant.

Animal ethics {#sec022}
-------------

The experiments involving the use of animals were done in accordance with guidelines of the "Institutional Animal Ethics Committee of National Institute of Immunology" which is under the control of CPCSEA. IAEC approval number was IAEC\#362 / 14.

Results {#sec023}
=======

Autophagy inducing potential of MIP Proteins, DNA and lipids {#sec024}
------------------------------------------------------------

Total proteins, genomic DNA and whole lipid fractions were obtained using the protocols described in methods section. RAW 264.7 macrophages were treated with different concentrations of these fractions for 12 h after which total cell lysate was prepared. Western blotting was performed to detect the level of lipidated LC3-II in these groups. MIP protein fraction was not able to induce autophagy in macrophages while MIP lipids and DNA resulted in nearly two-fold increase in autophagy induction (**[Fig 1](#pone.0224239.g001){ref-type="fig"})**.

![MIP lipids and DNA but not proteins induce autophagy in RAW 264.7 macrophages.\
RAW 264.7 macrophages were seeded (1 x 10^6^ per well) and stimulated with MIP protein lysate, MIP genomic DNA and MIP whole lipid fraction for 12 h. Figure shows Western blots depicting LC3-II level in macrophages stimulated with **(A)** MIP protein lysate (concentration ranging from 100 ng to 1000 ng) **(B)** MIP genomic DNA (100 ng to 4 μg) and **(C)** MIP lipids (250 ng to 100 μg). Significant fold change in LC3-II expression with respect to unstimulated control was observed between concentrations ranging from 500 ng to 1μg of MIP-DNA and 10 μg to 25 μg of whole lipid fraction.](pone.0224239.g001){#pone.0224239.g001}

Isolation of LAM and analysis of its immunostimulatory property {#sec025}
---------------------------------------------------------------

MIP-LAM was isolated as per the protocol described in methods section. Crude LAM obtained after chloroform: methanol (2:1) extraction was further purified by passing it through sephacryl S-100 column. Fractions collected were analyzed for the presence of LAM by estimating the carbohydrate content and by ELISA using commercially available LAM specific mAbs CS-35 and CS-40 **([Fig 2A](#pone.0224239.g002){ref-type="fig"})**. Fraction number 19 to 34 reacted strongly with mAbs and also had higher carbohydrate content. These fractions were pooled and further examined by SDS PAGE **([Fig 2B](#pone.0224239.g002){ref-type="fig"})**. A single diffused band was observed on the gel after silver staining. The identity of this diffused band as LAM was further confirmed by Western blotting **([Fig 2C](#pone.0224239.g002){ref-type="fig"})**.

![Isolation and purification of LAM.\
Crude LAM (10 mg/ml PBS) was passed through sephacryl S-100 column (equilibrated with PBS) at flow rate of 0.5 ml/min. Fractions of 3 ml each were collected. Carbohydrate content (dotted line, O.D. at 490 nm) and LAM content (Solid line, O.D. at 450 nm) in each fraction was determined by phenol-sulphuric acid method and by ELISA **(A)** Fractions 19 to 34 were pooled, concentrated and presence of LAM was confirmed by silver staining **(B)** and Western blotting **(C). Analysis of immunostimulatory property of MIP-LAM.** Macrophages / BMDCs were stimulated with varying concentrations of MIP-LAM / *M*.*tb-*LAM for 24 h. Level of TNF-α, IL-6 and IL-12 in the culture supernatant of macrophages **(D)** or BMDCs **(E)** was determined by ELISA. Data represents the mean with SEM of three independent experiments. \[\*: p ≤ 0.05; \*\*: p ≤ 0.01; \*\*\*: p ≤ 0.001; comparisons were made between cytokines induced by same concentration of MIP-LAM and *M*.*tb-*LAM\].](pone.0224239.g002){#pone.0224239.g002}

Fractions 35 to 46 showed low reactivity with monoclonal antibodies, indicating low LAM content in these fractions. This could be due to the presence of other carbohydrate molecules present along with LAM. Several components viz. lipomannan and phosphatidylinositol mannoside have been shown to be present along with LAM after phenol extraction step.

Further, immunostimulatory property of MIP-LAM was analyzed on macrophages and BMDCs and compared with that of *M*.*tb-*LAM. This was done by stimulating J774.1 macrophages / BMDCs with varying concentrations of MIP-LAM and *M*.*tb-*LAM for 24 h and supernatant was collected. The level of pro-inflammatory cytokines in culture supernatant was determined by ELISA. MIP-LAM stimulation resulted in higher amount of pro-inflammatory cytokines: TNF-α, IL-12 and IL-6 at concentrations ranging from 1 μg to 10 μg as compared to *M*.*tb-*LAM stimulated macrophages **([Fig 2D](#pone.0224239.g002){ref-type="fig"})** and BMDCs; very minimal level of these cytokines were observed upon stimulation with *M*.*tb-*LAM **([Fig 2E](#pone.0224239.g002){ref-type="fig"}).** These results provide evidence of immunostimulatory property of MIP-LAM on both cell types.

ROS and NO production in macrophages upon stimulation with MIP-LAM {#sec026}
------------------------------------------------------------------

To examine if MIP-LAM promote other antimicrobial defenses, ROS and NO production by MIP-LAM was studied. One group stimulated with LPS was taken as control. It was observed that ROS production was similar in LPS and MIP-LAM stimulated macrophages but NO production was very minimal in MIP-LAM group, while it was substantial in the LPS stimulated macrophages **([S1 Fig](#pone.0224239.s001){ref-type="supplementary-material"}).** These observations provide evidence that MIP-LAM has immunostimulatory effect on macrophages. Whereas, inhibitory metabolic effect of *M*.*tb*-LAM on macrophages, is well established in literature.

Autophagy induction potential of MIP-LAM {#sec027}
----------------------------------------

As MIP lipid fraction had shown high autophagy inducing potential and also, MIP-LAM demonstrated strong immunostimulatory property, we further analyzed its ability to induce autophagy in macrophages. Briefly, 1 x 10^6^ macrophages were seeded in 12-well plate and incubated with varying concentrations of MIP-LAM / *M*.*tb-*LAM for 2, 4, 8 and 12 h and lysate was prepared followed by Western blotting for LC3-II. Densitometry analysis of the LC3 blot indicated that MIP-LAM was able to induce significant level of autophagy as compared to untreated control and *M*.*tb-*LAM treated macrophages. Level of LC3-II was found to be higher in MIP-LAM group at all time points studied in comparison to *M*.*tb*-LAM group. However, at 2 h and 4 h of stimulation, maximum fold change in the LC3-II level was observed with MIP-LAM concentration of 2 μg and 5 μg. **([S2 Fig](#pone.0224239.s002){ref-type="supplementary-material"}).**

For further stimulation experiments, 4 h time point was used. Apart from LC3 Western blot, higher autophagy induction of MIP-LAM was confirmed by puncta formation assay where similar results were observed. Average puncta formed per cell were quantified in MIP-LAM / *M*.*tb-*LAM stimulated macrophages. MIP-LAM resulted in dense puncta formation whereas sparse puncta were observed in *M*.*tb-*LAM stimulated groups (**[Fig 3](#pone.0224239.g003){ref-type="fig"})**.

![MIP-LAM stimulation results in significant induction of autophagy in macrophages.\
RAW 264.7 macrophages were stimulated with varying concentrations of MIP-LAM / *M*.*tb-*LAM for 4 h. Lysates were prepared and Western blotting was performed to analyze the expression level of LC3-II. **(A)** Shown are the representative blots depicting the level of lipidated LC3-II in MIP-LAM / *M*.*tb-*LAM stimulated macrophages. **(B)** Graph depicting the mean fold change ± range in LC3-II level in all the groups. **(C)** RAW cells stimulated with MIP-LAM / *M*.*tb-*LAM were analyzed for LC3 puncta formation by immunofluorescence. Shown are the merged images of GFP-LC3 (green) and DAPI (blue) taken at 63 X magnification. **(D)** Graph showing average puncta formed per cell in LAM stimulated macrophages. The scale bar represents 5 μm. \*\*: P\<0.001, \*\*\*: P\<0.0001.](pone.0224239.g003){#pone.0224239.g003}

Assessment of co-localization of *M*.*tb* within phago-lysosomes {#sec028}
----------------------------------------------------------------

Since, MIP-LAM induced significantly high autophagy in macrophages; we further studied if it affects the co-localization of *M*.*tb* in lysosomes. Macrophages were infected with GFP expressing *M*.*tb*, and were subsequently stimulated with MIP-LAM or *M*.*tb-*LAM. MIP-LAM treatment resulted in significant increase in the co-localization of GFP expressing *M*.*tb* within the lysosomes (**[Fig 4A](#pone.0224239.g004){ref-type="fig"})**. *M*.*tb* presence inside the lysosomes was found to be 61% as compared to 24% in control unstimulated group while it was 41% in the whole lipid treated group **([Fig 4B](#pone.0224239.g004){ref-type="fig"})**. This suggests that MIP-LAM is an important component of lipid fraction of MIP responsible for enhanced co-localization of *M*.*tb* within the lysosomes. However, in *M*.*tb-*LAM stimulated group, the co-localization was approximately 21%, which was similar to that of unstimulated control group.

![Stimulation with MIP-LAM increases co-localization of *M*.*tb* within the phago-lysosomes.\
RAW 264.7 macrophages were infected with GFP expressing *M*.*tb* for 4 h with subsequent stimulation with MIP-LAM / *M*.*tb-*LAM for another 4 h. Lysosomes were stained with LysoTracker-Red and visualised by confocal microscope. From each group, 50 fields were examined and total number of green spots (GFP expressing *M*.*tb* located outside the lysosomes) and of yellow spots (observed when GFP expressing *M*.*tb* co-localizes with LysoTracker-Red giving a yellow fluorescence) were counted. **(A)** Representative images showing co-localization of *M*.*tb* within the lysosomes. Yellow and white circles are the representations of *M*.*tb* located inside and outside of the lysosomes of the macrophages, respectively. Scale bar, 10 μm. **(B)** Graph depicting the percentage of *M*.*tb* co-localized within the lysosomes. \*: P\< 0.01, \*\*: P\<0.001.](pone.0224239.g004){#pone.0224239.g004}

Effect of MIP-LAM on survival of *M*.*tb* in the infected macrophages {#sec029}
---------------------------------------------------------------------

Next, we examined the effect of MIP-LAM on survival of *M*.*tb* in the macrophages. Macrophages were first infected with GFP expressing *M*.*tb* for 4 h. Subsequently, the cells were stimulated with MIP-LAM / *M*.*tb-*LAM for another 4 h. Thereafter, lysate was prepared and plated on hygromycin containing 7H11-agar plates. CFU were counted and percentage survival of *M*.*tb* was calculated. Stimulation with MIP-LAM resulted in approximately 65% decrease in *M*.*tb* CFU count while MIP whole lipid fraction treatment reduced the *M*.*tb* CFU count by 50% as compared to unstimulated control group. *M*.*tb-*LAM had only minimal effect where *M*.*tb* CFU reduction was only 15% **([Fig 5](#pone.0224239.g005){ref-type="fig"})**.

![MIP-LAM stimulation leads to enhanced clearance of *M*.*tb* from infected macrophages.\
Macrophages were infected with GFP expressing *M*.*tb* for 4 h and subsequent stimulation with varying concentrations of MIP-LAM/ *M*.*tb-*LAM for 4 h. Group stimulated with MIP whole lipid fraction was taken for comparison. Cells lysate was prepared and plated (100 μl from each group) in triplicates on 7H11-agar plates. Shown here is the mean CFU count of *M*.*tb* from 4 independent experiments. \*\*\*: P\<0.0001.](pone.0224239.g005){#pone.0224239.g005}

Discussion {#sec030}
==========

Mycobacterial species induce autophagy in macrophages but the extent of induction varies with species \[[@pone.0224239.ref012]\]. The non-pathogenic species induce strong autophagic response in macrophages whereas pathogenic ones are known to suppress autophagy which form a part of their survival strategies within the host cells. However, this suppression/ inhibition of autophagy is caused by certain mycobacterial components including lipoproteins (LpqH, LprE) and glycolipids (phosphatidyl-*myo*-inositol mannosides, lipomannans, lipoarabinomannan) which have the ability to limit host autophagy responses to the pathogens \[[@pone.0224239.ref015],[@pone.0224239.ref021]--[@pone.0224239.ref024]\]. In recent past, we have reported MIP to be a potent inducer of autophagy. The main focus of this study was to determine the fractions of MIP which possess the ability to induce autophagic response. Protein fraction was incapable of inducing autophagy, whereas genomic DNA showed some autophagic response but it was less than that of lipid fraction which exhibited significant induction of autophagy **([Fig 1](#pone.0224239.g001){ref-type="fig"})**. These results are consistent with previous findings where it has been shown that lipids are crucial in membrane remodeling, formation of autophagosomes and signal transduction process which lead to completion of autophagy process \[[@pone.0224239.ref025],[@pone.0224239.ref026]\].

These results encouraged us to isolate LAM from MIP and to study its attributes. LAM, which is ubiquitously found in all species of mycobacteria, is a complex molecule containing a phosphatidylinositol (PI) moiety anchoring a large mannose core to the mycobacterial cell wall \[[@pone.0224239.ref027]\]. The pathogenic mycobacteria mainly *M*.*tb* and *M*.*leprae* possess Mannose-capped lipoarabinomannan (ManLAM); whereas, rapidly growing mycobacterial species have Arabinose-LAM \[[@pone.0224239.ref028],[@pone.0224239.ref029]\]. LAM exhibits a wide range of immunomodulatory functions and is considered to be a critical factor which helps mycobacteria to modulate phagocyte functions contributing to the persistence of mycobacteria within macrophages \[[@pone.0224239.ref027],[@pone.0224239.ref030],[@pone.0224239.ref031]\]. *M*.*tb-*LAM has been reported to be responsible for a few distinct features of *M*.*tb* in phagocytic cells, inclusive of phagosome maturation arrest, autophagy inhibition, inhibition of macrophage apoptosis and limiting the production of pro-inflammatory cytokines \[[@pone.0224239.ref032]\].

Autophagy induction by MIP lipids co-relates to our ongoing concurrent studies where we have shown that MIP induced autophagy is mediated by the TLR2 signaling recognized by mycobacterial LAM. It is possible that MIP-LAM could be the crucial component responsible for autophagy induction in macrophages. In addition to LAM, other glycolipids including lipomannan, phosphatidyl-myo-inositol mannoside (PIM) and trehalosedimycolate (TDM), as well as certain tri-acylated lipoproteins present in *M*.*tb* cell-wall are also reported to interact with TLR2 leading to activation of immune cells \[[@pone.0224239.ref033]\].

Properties of LAM leading to activation of macrophages and other immune cells have been extensively studied. Ara-LAM from non-pathogenic (fast growing) mycobacterial species is known to be more potent than Man-LAM from pathogenic mycobacteria (slow growing particularly *M*.*tb*) in stimulating the macrophages to evoke secretion of cytokines \[[@pone.0224239.ref034]\]. Ara-LAM exhibits the ability to elicit high TNF-α production in macrophages, whereas little or negligible amount of TNF-α production is seen in response to the treatment with Man-LAM \[[@pone.0224239.ref035],[@pone.0224239.ref036]\]. Besides, Ara-LAM has also displayed the capacity to trigger production of various other cytokines including IL-6, IL-8, IL-10, and IL-12 by the host cells \[[@pone.0224239.ref030],[@pone.0224239.ref037]\]. Very similar to these results, we also observed that MIP-LAM isolated from MIP, which is a non-virulent mycobacterium, resulted in the production of significantly high levels of TNF-α in macrophages, whereas *M*.*tb-*LAM treatment was not able to induce notable TNF-α production **([Fig 2](#pone.0224239.g002){ref-type="fig"}).**

*M*.*tb*-LAM is reported to inhibit autophagy as well as phago-lysosome fusion in macrophages. In this study, autophagy inducing ability of MIP-LAM was examined. Interestingly, stimulation of macrophages with MIP-LAM resulted in high induction of autophagy as compared to unstimulated control **([Fig 3](#pone.0224239.g003){ref-type="fig"}).** MIP-LAM stimulated macrophages displayed significantly high percentage of *M*.*tb* co-localization in the phago-lysosomal compartments unlike that of *M*.*tb-*LAM **([Fig 4](#pone.0224239.g004){ref-type="fig"}).** Also, MIP-LAM resulted in decreased survival of *M*.*tb* in infected macrophages. The percentage survival of *M*.*tb* in MIP-LAM stimulated groups was comparable to that of macrophages stimulated with MIP whole lipid fraction **([Fig 5](#pone.0224239.g005){ref-type="fig"})**.

This study shed light on the autophagy inducing potential of different fractions of MIP, particularly LAM isolated from lipid fraction. This is a probing study, providing evidence of crucial role of MIP-LAM in clearance of *M*.*tb* from the host by inducing secretion of pro-inflammatory cytokines as well as by inducing autophagy. Further characterization of MIP-LAM will throw light on its composition and would elaborate its other attributes.

Supporting information {#sec031}
======================

###### MIP-LAM induces high ROS but minimal NO in macrophages.

**(A)** RAW macrophages were left unstimulated or stimulated with LPS (1 μg/mL) or MIP-LAM (5 μg/mL) for 24 h. Supernatant was collected and estimated for NO with Griess reagent. **(B)** ROS in macrophages was determined by using 2\',7\'-dichlorodihydrofluorescein diacetate (H~2~DCFDA) dye. Fluorescence was determined using fluorimeter excitation at 490 nm and emission at 524 nm. H~2~O~2~ (100 μM) was used as a positive control. \*\*\*: P\<0.0001.

(TIF)

###### 

Click here for additional data file.

###### Kinetics of LC3-II level induced by MIP-LAM/ *M*.*tb*-LAM.

RAW 264.7 macrophages were stimulated with various concentrations of MIP-LAM / *M*.*tb*-LAM for 2, 4, 8 and 12 h. Shown are the Western blots for the indicated time points.

(TIF)

###### 

Click here for additional data file.
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BSA
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CFU

:   Colony forming units
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:   4′,6-Diamidine-2′-phenylindole dihydrochloride

H~2~DCFDA

:   2\',7\'-dichlorodihydrofluorescein diacetate

DMEM

:   Dulbecco's Modified Eagle Media

LAM

:   Lipoarabinomannan

MIP

:   *Mycobacterium indicus pranii*

*M.tb*

:   *Mycobacterium tuberculosis*

PBS

:   Phosphate buffered saline

LC3

:   Microtubule-associated proteins 1A/1B light chain 3B

PFA

:   Paraformaldehyde
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:   Polyvinylidenedifluoride

RPMI

:   Roswell Park Memorial Institute medium

TB

:   Tuberculosis
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Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Our internal editors have looked over your manuscript and determined that it is within the scope of our Autophagy and Proteostasis Call for Papers. This collection of papers is headed by a team of Guest Editors: Sharon Tooze, Fulvio Regiori and Thorsten Hoope. The Collection will encompass a diverse range of research articles from early initiation of autophagy, to understand the role other proteostasis pathways play in maintaining cellular homeostasis and the cross talk between the two.  Additional information can be found on our announcement page: <https://collections.plos.org/s/autophagy-proteostasis>.
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3\. Thank you for including your ethics statement: \"The experiments involving the use of animals were done in accordance with the Institute's Animal Ethics guidelines. IAEC approval number was IAEC\#362/ 14\"
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4\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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2\. Has the statistical analysis been performed appropriately and rigorously?
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript submitted by Bhaskar and colleagues reports on the immunostimulatory properties of lipoarabinomannan from Mycobacterium indicus pranii (MIP-LAM). Authors showed that MIP-LAM induces autophagy and proinflammatory cytokines in murine macrophages. They found that MIP-LAM promotes acidification of Mycobacterium tuberculosis (MTB)-containing compartment and killing of the MTB in macrophages. Overall, this set of data demonstrates that MIP-LAM activates antimicrobial defenses of macrophages.

Major comments:

-It would be important to add the following controls to show that immunostimulatory properties is not due to LPS contamination and that decrease of CFU is not due to increase in cell death.

-Does MIP-LAM promote other antimicrobial defenses such as ROS and NO production?

-Authors compare MIP-LAM with MTB-LAM. It would have been interesting to compare with the LAM from another non-pathogenic mycobacteria such as M.smegmatis.

-Regarding autophagy assays: it would be important to do a kinetic with one concentration of LAM (compare MIP-LAM and MTB-LAM) and to measure autophagic flux by adding lysosome inhibitors (see Klionsky et al. Guidelines. Autophagy. 2016).

-The ratios of LC3-II/actin need to be measured and display at the bottom of the blots.

-Some references are missing: l72, l78, l424. L424: which lipoproteins and glycolipids? Please add reference "Sui et al. 2011. J Proteome Res" for lipoarabinomannan and autophagy and "Bah et al. 2016. Front Cell Infect Microbiol" for lipoglycan and autophagy.

-Please add a paragraph in materials & methods for LC3 westernblot.

-l277: authors indicate that lysotracker was added after fixing. The standard protocol indicates an incubation with living cells then fixing: <https://www.thermofisher.com/order/catalog/product/L7528>. I am not sure that the assay was done properly. Please clarify and give a reference for the protocol (from another laboratory).

-l303: please be more specific: fold of increase, concentration.
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-Figure1: please label properly the figure, what are the bottom and upper blots?
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-l272: please change "co-localization of M.tb in lysosomes of LAM stimulated macrophages" to "co-localization of M.tb with lysosomes in LAM-stimulated macrophages".

-l301: please change "LC3" to "LC3-II"

-Figure 3 legend: indicate scale bar, change ug; in panel D remove one (.

-Figure 4 legend: please change "no" to "number" and add "of" before "yellow"; indicate scale bar; what are those white circles?

-l412: remove (A)
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If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Journal Requirements

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: For the current submission, we have ensured that the manuscript meets PLOS ONE's requirements.

2\. Our internal editors have looked over your manuscript and determined that it is within the scope of our Autophagy and Proteostasis Call for Papers. This collection of papers is headed by a team of Guest Editors: Sharon Tooze, Fulvio Regiori and Thorsten Hoope. The Collection will encompass a diverse range of research articles from early initiation of autophagy, to understand the role other proteostasis pathways play in maintaining cellular homeostasis and the cross talk between the two. Additional information can be found on our announcement page: <https://collections.plos.org/s/autophagy-proteostasis>.

If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

Response: Yes, please consider this manuscript for the collection- "Autophagy and Proteostasis". We have mentioned the same in our cover letter.

3\. Thank you for including your ethics statement: \"The experiments involving the use of animals were done in accordance with the Institute's Animal Ethics guidelines. IAEC approval number was IAEC\#362/ 14\"

Please amend your current ethics statement to include the full name of the ethics committee that approved your specific study.

For additional information about PLOS ONE submissions requirements for animal ethics, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-animal-research>.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

Response: We have amended the ethics statement in the revised manuscript. The full name of the animal ethics committee is "Institutional Animal Ethics Committee of National Institute of Immunology" under control of CPCSEA. We will also amend the "Ethics Statement" in submission form.

4\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Response:This study doesn't involve any repository information. All relevant data has been provided in the manuscript and there is no additional data to upload. Please change our Data availability statement.

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

5\. Review Comments to the Author

Reviewer \#1: The manuscript submitted by Bhaskar and colleagues reports on the immunostimulatory properties of lipoarabinomannan from Mycobacterium indicus pranii (MIP-LAM). Authors showed that MIP-LAM induces autophagy and proinflammatory cytokines in murine macrophages. They found that MIP-LAM promotes acidification of Mycobacterium tuberculosis (M.tb)-containing compartment and killing of the M.tb in macrophages. Overall, this set of data demonstrates that MIP-LAM activates antimicrobial defenses of macrophages.

Major comments:

-It would be important to add the following controls to show that immunostimulatory properties is not due to LPS contamination and that decrease of CFU is not due to increase in cell death.

Response:LPS is immune-stimulatory component of gram-negative bacteria while LAM is an antigenic glycolipid component of genus Mycobacterium. It is reported that Mycobacterial antigens generate different metabolic responses in macrophages as compared to gram-negative effectors. Further, there was no chance of contamination of MIP culture with any other gram-negative bacteria. All steps were done in sterile condition with proper quality control checks.

As suggested, we analyzed LPS as control also while examining the ROS and NO production by MIP-LAM. It was observed that ROS production was similar in LPS and MIP-LAM stimulated macrophages but NO production was very minimal in MIP-LAM group, while it was substantial in the LPS stimulated macrophages {Fig 1 (A & B)}. These observations also provide indirect evidence that MIP-LAM is not contaminated with LPS.

Decrease in CFU of M.tb was due to increased phago-lysosome fusion in 'M.tb+MIP-LAM' group (Figure 4 of Manuscript) which resulted in enhanced clearance of M.tb from the infected macrophages.

-Does MIP-LAM promote other antimicrobial defenses such as ROS and NO production?

Response: As suggested, we examined the ROS and NO production by MIP-LAM. One group stimulated with LPS was taken as control. It was observed that ROS production was similar in LPS and MIP-LAM stimulated macrophages but NO production was very minimal in MIP-LAM group, while it was substantial in the LPS stimulated macrophages {Figure 1 (A & B)}. These observations provide evidence that MIP-LAM has immunostimulatory effect on macrophages. Whereas, inhibitory metabolic effect of M.tb-LAM on macrophages, is well established in literature.

A\)

B\)

Fig 1: (A) RAW macrophages were left unstimulated or stimulated with LPS (1 µg/mL) or MIP LAM (5 µg/mL) for 24 hours. Supernatant was collected and estimated for NO with Griess reagent. (B) Macrophages were incubated with 20 µM 2\',7\'-dichlorodihydrofluorescein diacetate (H2DCFDA) dye for 45 min at 37 �C under dark conditions. Cells were then washed and stimulated with LPS (1 µg/mL) / MIP-LAM (5 µg/mL). Fluorescence was determined using fluorimeter excitation at 490 nm and emission at 524 nm. H2O2 (100 µM) was used as a positive control.

-Authors compare MIP-LAM with MTB-LAM. It would have been interesting to compare with the LAM from another non-pathogenic mycobacteria such as M.smegmatis.

Response: As MIP was found to be potent inducer of autophagy in previous study by our group hence, aim of this study was to further examine the component/s of MIP responsible for autophagy induction. Interestingly, we found that MIP lipids and DNA were able to induce autophagy and not the protein fraction. As LAM is one of the crucial component of mycobacterial cell wall lipids possessing immunomodulatory activity; we isolated LAM from MIP and did a comparative study with M.tb-LAM, as idea was to compare it with pathogenic mycobacteria.

LAM from non-pathogenic mycobacteria including M.smegmatis had already been reported to have immunomodulatory properties (Das et al., 2015). In future studies where we will further characterize MIP-LAM, we would also add M.smegmatis LAM as a control.

-Regarding autophagy assays: it would be important to do a kinetic with one concentration of LAM (compare MIP-LAM and MTB-LAM) and to measure autophagic flux by adding lysosome inhibitors (see Klionsky et al. Guidelines. Autophagy. 2016).

Response: In initial standardization experiments kinetics study was done with MIP-LAM /M.tb- LAM where macrophages were stimulated for 2/4/8/12 h. Shown below are the Western blots of lysate prepared at different time points (Figure 2). LC3-II levels were found to be higher in MIP-LAM group at all time points studied as compared to M.tb-LAM group.

In our previous published study where we examined the autophagy inducing potential of whole MIP and M.tb, it was observed that both MIP and M.tb induced autophagy to the similar extent as observed from the levels of LC3-II expression. Hence, we further analyzed the autophagic flux and observed that MIP maintained the complete autophagic flux while M.tb inhibited the fusion of autophagosome with lysosome. But in the present study there was significantly higher induction of LC3-II by MIP-LAM as compared to M.tb-LAM at all the concentrations studied (Figure 3 of manuscript). Similarly, significantly higher numbers of puncta per cell were observed in the MIP-LAM stimulated group as compared to M.tb-LAM group which provides evidence of higher autophagy induction by MIP-LAM as compared to M.tb-LAM. Further, complete autophagic flux in the MIP-LAM stimulated group was confirmed by phago-lysosome fusion study where significantly higher numbers of M.tb bacilli were observed in the lysosome compartment in MIP-LAM stimulated group as compared to M.tb-LAM group (Figure 4 of manuscript).

Fig 2. Macrophages were stimulated with varying concentration of MIP-LAM/ M.tb-LAM for 2, 4, 8 and 12 h. Western blotting for LC3-II was done and density was quantified using Image J software. Shown here are the blots depicting LC3-II levels in MIP-LAM / M.tb-LAM stimulated macrophages.

-The ratios of LC3-II/actin need to be measured and display at the bottom of the blots.

Response: The ratios of LC3-II/actin have been measured and displayed at the bottom of the blots.

-Some references are missing: l72, l78, l424. L424: which lipoproteins and glycolipids? Please add reference "Sui et al. 2011. J Proteome Res" for lipoarabinomannan and autophagy and "Bah et al. 2016. Front Cell Infect Microbiol" for lipoglycan and autophagy.

Response: We are sorry for the mistake. The missing references have been included in the revised manuscript along with above mentioned references.

-Please add a paragraph in materials & methods for LC3 western blot.

Response: In the materials & methods section of the revised manuscript, a paragraph on LC3 western blot has been added.

-l277: authors indicate that lysotracker was added after fixing. The standard protocol indicates an incubation with living cells then fixing: <https://www.thermofisher.com/order/catalog/product/L7528>. I am not sure that the assay was done properly. Please clarify and give a reference for the protocol (from another laboratory).

Response: We are sorry for this. It was mistakenly written in methods. The incubation with lysotracker was done on live cells only. The cells were fixed thereafter. We have corrected the same in the manuscript.

-l303: please be more specific: fold of increase, concentration.

Response: We are sorry for the confusion. We have mentioned the autophagy induction by lipids and DNA in the form of fold increase as suggested.

-l306: please indicate incubation time.

Response: We have indicated the incubation time (12 h) in the manuscript.

-Figure1: please label properly the figure, what are the bottom and upper blots?

Response: Figure 1 has been labeled accordingly. These are representative blots showing LC3 expression, where upper blot represents MIP protein stimulated samples, the middle one represents MIP DNA stimulated samples and the lower one is for MIP lipid stimulated groups.

Minor comments:

-Please spell "TE" out (l141)

Response: "TE" has been spelled out in the revised manuscript.

-l269: please change "flour" to "fluor"

Response: In line 269, "flour" has been changed to "fluor".

-l272: please change "co-localization of M.tb in lysosomes of LAM stimulated macrophages" to "co-localization of M.tb with lysosomes in LAM-stimulated macrophages".

Response: The above heading has been accordingly modified in the revised manuscript.

-l301: please change "LC3" to "LC3-II"

Response: "LC3" has been modified to "LC3-II".

-Figure 3 legend: indicate scale bar, change ug; in panel D remove one (.

Response: In Figure 3 legend of the revised manuscript, above mentioned changes have been made.

-Figure 4 legend: please change "no" to "number" and add "of" before "yellow"; indicate scale bar; what are those white circles?

Response: In figure 4 legend, the required modifications have been done as well as scale bars have been indicated. White circles shown in the images were to highlight the localization of GFP expressing M.tb, either inside (yellow spots) or outside (green spots) the lysosomes in various experimental groups.

To avoid confusion, we have now changed the color used for highlighting the bacilli. Now, yellow circles represent bacilli inside lysosomes and white circles represent bacilli outside the lysosomes. Further, we have highlighted only few bacilli (n=5) using circles as these were many in number and if all bacilli would have been marked with circles then the images will appear cluttered.

-l412: remove (A)

Response: (A) has been removed from the figure legend.
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Click here for additional data file.
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Dear Dr. Bhaskar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Additional experiments performed for the revision are important and should be included, described and analyzed in the revised manuscript.

We would appreciate receiving your revised manuscript by Oct 06 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Jérôme Nigou

Academic Editor

PLOS ONE
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr. Bhaskar,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jérôme Nigou

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0224239.r006

Acceptance letter

Nigou

Jérôme

Academic Editor

© 2019 Jérôme Nigou

2019

Jérôme Nigou

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

14 Oct 2019

PONE-D-19-15439R2

Lipoarabinomannan from Mycobacterium indicus pranii shows immunostimulatory activity and induces autophagy in macrophages

Dear Dr. Bhaskar:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jérôme Nigou

Academic Editor

PLOS ONE
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